Inventor · disambiguated record
Joel D. Moore
Also filed as: MOORE JOEL · MOORE JOEL D
14 granted patents·7 pending applications·149 citations·filing 2006–2022
91Inventor score
Files withENANTA PHARM INC6NIU DEQIANG5SYROS PHARMACEUTICALS INC4DANA FARBER CANCER INST INC2MOORE JOEL D2
Top patents by PatentIndex Score
21 records- 0197US7605126B2Acylaminoheteroaryl hepatitis C virus protease inhibitorsENANTA PHARM INC·Filed 2006·Granted Oct 20, 2009·38 cites·15 claims
- 0297US7582605B2Phosphorus-containing hepatitis C serine protease inhibitorsENANTA PHARM INC·Filed 2006·Granted Sep 1, 2009·59 cites·9 claims
- 0393US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0491US10047070B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2014·Granted Aug 14, 2018·17 cites·19 claims
- 0584US10906889B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2018·Granted Feb 2, 2021·4 cites·32 claims
- 0683US8211891B2Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitorsGAI YONGHUA·Filed 2009·Granted Jul 3, 2012·4 cites·188 claims
- 0782US8030307B2Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 proteaseENANTA PHARM INC·Filed 2008·Granted Oct 4, 2011·6 cites·17 claims
- 0880US7906513B2Hydrazide-containing hepatitis C serine protease inhibitorsENANTA PHARM INC·Filed 2007·Granted Mar 15, 2011·5 cites·10 claims
- 0979US8263549B2C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitorsMOORE JOEL D·Filed 2008·Granted Sep 11, 2012·6 cites·18 claims
- 1079US7718612B2Pyridazinonyl macrocyclic hepatitis C serine protease inhibitorsENANTA PHARM INC·Filed 2007·Granted May 18, 2010·1 cites·4 claims
- 1175US8501681B2Macrocyclic hepatitis C virus serine protease inhibitorsNIU DEQIANG·Filed 2007·Granted Aug 6, 2013·2 cites·15 claims
- 1260US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1360US2024368132A1Rock2 inhibitors and uses thereofHARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 1459US2009005387A1Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitorsNIU DEQIANG·Filed 2008·Application pending·0 cites
- 1556US8809264B2Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitorsNIU DEQIANG·Filed 2007·Granted Aug 19, 2014·0 cites·15 claims
- 1653US2016264552A1Heteromaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1752US8962551B2Quinoxalinyl derivativesNIU DEQIANG·Filed 2008·Granted Feb 24, 2015·0 cites·15 claims
- 1851US8383583B2Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitorsENANTA PHARM INC·Filed 2008·Granted Feb 26, 2013·0 cites·20 claims
- 1951US2019292167A1Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2047US2008267917A1N-functionalized amides as hepatitis c serine protease inhibitorsNIU DEQIANG·Filed 2007·Application pending·0 cites
- 2141US2009035267A1Acyclic, pyridazinone-derived hepatitis c serine protease inhibitorsMOORE JOEL D·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joel D. Moore files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →